Tevogen Bio Holdings Inc. (TVGN) announced continued progress on a series of strategic acquisition initiatives that the company says could collectively support approximately $100 million in combined annual revenue, if completed. Shares of the company moved higher following the update.
The company noted that it is evaluating the acquisition of a contract research organization (CRO), along with additional opportunities aligned with its broader healthcare platform.
These initiatives are intended to complement Tevogen's existing business and support its long-term goal of becoming a financially self-sustaining healthcare enterprise. Tevogen said the potential transactions could help expand the company into a three-pillar structure: Tevogen Bio (biotechnology), Tevogen.AI (technology), and a future healthcare services arm that may include management service and contract research operations.
Founder and CEO Ryan Saadi, MD, MPH, emphasized that capital discipline remains a core priority, stating that any acquisition will be guided by strategic fit, long-term value creation, and responsible stewardship of the company's capital structure. He added that the goal is to build a healthcare enterprise with the financial strength to support operations, advance growth initiatives, and generate sustainable revenue. Tevogen describes itself as a socially integrated healthcare enterprise focused on affordability, efficiency, and scientific rigor. Its biotechnology arm, Tevogen Bio, has completed a proof-of-concept clinical trial demonstrating the potential of its single HLA-restricted, genetically unmodified allogeneic T-cell therapy, built on its proprietary ExacTcell platform. The company's pipeline spans virology, oncology, and neurology.
The company recently implemented a 1-for-50 reverse stock split on March 2, 2026.
TVGN closed Thursday's trading at $8.04, up 11.82%. During overnight trading the stock is at $8.55, up 6.34%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.